FDA pauses Mersana’s clinical trial after patient dies

The FDA has paused Mersana Therapeutics’ Phase I clinical trial for a cancer treatment after a patient died, the biotech said Monday morning.

The death was deemed to be related to its drug, the Cambridge, MA-based biotech said.